Methyl 3-[(8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoylsulfamoyl]-1-propan-2-ylpyrazole-5-carboxylate
C21H25FN4O5S — CID 170717791
Data last refreshed: (MolForge compound catalog, from PubChem)
About Methyl 3-[(8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoylsulfamoyl]-1-propan-2-ylpyrazole-5-carboxylate
Methyl 3-[(8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoylsulfamoyl]-1-propan-2-ylpyrazole-5-carboxylate (PubChem CID 170717791) has the molecular formula C21H25FN4O5S and a molecular weight of 464.52 g/mol. Its IUPAC name is methyl 3-[(8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoylsulfamoyl]-1-propan-2-ylpyrazole-5-carboxylate.
Molecular Properties
| Compound Name | Methyl 3-[(8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoylsulfamoyl]-1-propan-2-ylpyrazole-5-carboxylate |
|---|---|
| PubChem CID | 170717791 |
| Molecular Formula | C21H25FN4O5S |
| Molecular Weight | 464.52 g/mol |
| Exact Mass | 464.15 |
| IUPAC Name | methyl 3-[(8-fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoylsulfamoyl]-1-propan-2-ylpyrazole-5-carboxylate |
| SMILES | COC(=O)c1cc(S(=O)(=O)NC(=O)Nc2c3c(c(F)c4c2CCC4)CCC3)nn1C(C)C |
| InChI | InChI=1S/C21H25FN4O5S/c1-11(2)26-16(20(27)31-3)10-17(24-26)32(29,30)25-21(28)23-19-14-8-4-6-12(14)18(22)13-7-5-9-15(13)19/h10-11H,4-9H2,1-3H3,(H2,23,25,28) |
| InChIKey | CFRCKQSHFRQPSL-UHFFFAOYSA-N |
| XLogP | 2.88 |
| TPSA | 119.39 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 464.52 |
| LogP ≤ 5 | 2.88 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 170717791 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.